Special Issue

Personalised Cancer Vaccines

Message from the Guest Editor

Personalized mRNA cancer vaccines are a form of immunotherapy treatment that is currently being tested in clinical trials. They are tailored to each person's cancer and work by training the immune system to recognize, destroy, and prevent the spread of cancer cells. In recent years, there has been a renewed interest in personalized cancer vaccines, primarily due to the use of innovative technologies to identify neoantigens and novel vaccine delivery platforms. In this Special Issue, novel cancer vaccines, adjuvants, and therapeutics will be examined, with regard to their regulation and treatment of disease. Cancer vaccines are coming.

Guest Editor

Dr. Andrew L. Coveler

Medical Oncology Unit, University of Washington School of Medicine, Seattle, WA, USA

Deadline for manuscript submissions

30 April 2026



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/219014

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

